Login to Your Account


More drug pricing red tape or potential solutions?

By Lynn Yoffee
News Director

Monday, October 17, 2016

Unpacking the complex U.S. drug pricing system to fix it starts with understanding how it works. It's become clear that many who make the rules are woefully unclear about a system that's rife with a lack of transparency, multilevel negotiations, hidden markups, cost shares, usual and customary prices, and a host of patient assistance programs (PAPs).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription